Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CODX 
Co-Diagnostics Inc (CODX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: CODX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.8% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.42M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.15 | 52 Weeks Range 0.23 - 1.55 | Updated Date 11/9/2025 |
52 Weeks Range 0.23 - 1.55 | Updated Date 11/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.155 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4946.14% |
Management Effectiveness
Return on Assets (TTM) -38.09% | Return on Equity (TTM) -63.4% |
Valuation
Trailing PE - | Forward PE 16 | Enterprise Value 5431513 | Price to Sales(TTM) 24.34 |
Enterprise Value 5431513 | Price to Sales(TTM) 24.34 | ||
Enterprise Value to Revenue 5.41 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 60144854 | Shares Floating 36416342 |
Shares Outstanding 60144854 | Shares Floating 36416342 | ||
Percent Insiders 5.04 | Percent Institutions 11.68 |
Upturn AI SWOT
Co-Diagnostics Inc
Company Overview
History and Background
Co-Diagnostics, Inc. was founded in 2013. It focuses on developing and commercializing molecular diagnostic products. The company gained prominence during the COVID-19 pandemic with its COVID-19 tests and has since expanded its product offerings in the diagnostics space.
Core Business Areas
- Molecular Diagnostics: Develops and commercializes real-time polymerase chain reaction (PCR) diagnostic products for the detection of infectious diseases, liquid biopsy for cancer screening, and other applications. The company also provides contract manufacturing services for companies requiring IVD and cGMP assays.
- Logistics: Provides shipping and cold chain logistical services
Leadership and Structure
Dwight Egan is the CEO. The company has a board of directors and operates with typical functional departments like R&D, Sales, Marketing, and Operations.
Top Products and Market Share
Key Offerings
- Logistics: Shipping and cold chain logistical services. Market share data is not available. Competitors include UPS Healthcare and FedEx Healthcare
- MDx 3baseu2122 technology: A proprietary platform for engineering and designing PCR primers. Market share and revenue data is not publicly available. Competitors include Thermo Fisher Scientific (TMO) and Roche (RHHBY).
- CoPrimeru2122: A proprietary technology designed for in-vitro diagnostic tests. Revenue and market share data are not publicly available. Competitors include Thermo Fisher Scientific (TMO) and Roche (RHHBY).
Market Dynamics
Industry Overview
The molecular diagnostics industry is experiencing growth driven by advancements in technology, increasing prevalence of infectious diseases, and a growing demand for personalized medicine.
Positioning
Co-Diagnostics Inc. competes with major players in the molecular diagnostics space and aims to gain market share through its proprietary technologies and focus on cost-effective solutions.
Total Addressable Market (TAM)
The global molecular diagnostics market is projected to reach hundreds of billions of dollars. Co-Diagnostics Inc. targets specific segments with its technology and products, aiming to capture a portion of the overall market.
Upturn SWOT Analysis
Strengths
- Proprietary MDx 3baseu2122 technology platform
- Experience in developing and commercializing PCR diagnostic products
- Established infrastructure for test development and manufacturing
- Vertically integrated logistical services
Weaknesses
- Limited brand recognition compared to larger competitors
- Reliance on a small number of products for revenue
- Susceptible to revenue decline post-pandemic
- Lower R&D budget than competitors
Opportunities
- Expanding product offerings in areas beyond infectious diseases
- Entering new geographic markets
- Acquiring complementary technologies or businesses
- Partnering with larger companies for distribution
Threats
- Competition from larger, more established companies
- Changes in regulatory requirements
- Technological advancements that could render current products obsolete
- Market share may continue to decline post-pandemic
Competitors and Market Share
Key Competitors
- TMO
- RHHBY
- DGX
- LH
Competitive Landscape
Co-Diagnostics Inc. faces significant competition from larger, more established companies with greater resources and broader product offerings. Co-Diagnostics Inc.'s competitive advantage lies in its proprietary technologies and cost-effective solutions, but it must continue to innovate and expand its product portfolio to remain competitive.
Growth Trajectory and Initiatives
Historical Growth: Co-Diagnostics experienced rapid growth during the COVID-19 pandemic due to high demand for its diagnostic tests. Growth has slowed as the pandemic has declined.
Future Projections: Future growth depends on Co-Diagnostics Inc.'s ability to diversify its product portfolio and expand into new markets. Analyst estimates vary widely.
Recent Initiatives: Focus on expanding product line into infectious diseases, liquid biopsy for cancer screening, and contract manufacturing.
Summary
Co-Diagnostics Inc. experienced rapid growth during the COVID-19 pandemic but faces challenges in sustaining that growth in a more competitive post-pandemic market. The company's proprietary technologies and focus on cost-effective solutions are strengths, but it needs to diversify its product portfolio and expand its market reach to ensure long-term success. Monitoring of regulatory changes and technological advancements are critical.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Industry Reports
- Third-Party Financial Data Providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market conditions and company performance can change, and actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Co-Diagnostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2017-07-12 | Chairman & CEO Mr. Dwight H. Egan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 132 | Website https://co-dx.com |
Full time employees 132 | Website https://co-dx.com | ||
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.